Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Kazia Therapeutics Ltd ADR (KZIA)
Kazia Therapeutics Ltd ADR (KZIA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,162
  • Shares Outstanding, K 16,341
  • Annual Sales, $ 20 K
  • Annual Income, $ -13,780 K
  • 60-Month Beta 2.18
  • Price/Sales 612.17
  • Price/Cash Flow N/A
  • Price/Book 1.29
Trade KZIA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/30/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 322.57% ( -160.34%)
  • Historical Volatility 157.58%
  • IV Percentile 35%
  • IV Rank 24.76%
  • IV High 961.69% on 12/30/22
  • IV Low 112.22% on 04/03/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 26
  • Volume Avg (30-Day) 18
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 95
  • Open Int (30-Day) 33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4000 +12.75%
on 11/03/23
0.8784 -48.66%
on 11/15/23
+0.0405 (+9.87%)
since 11/01/23
3-Month
0.3215 +40.28%
on 10/31/23
1.1500 -60.78%
on 09/06/23
-0.5190 (-53.51%)
since 09/01/23
52-Week
0.3215 +40.28%
on 10/31/23
1.6800 -73.15%
on 04/18/23
-0.1840 (-28.98%)
since 12/01/22

Most Recent Stories

More News
Kazia announces voluntary delisting from ASX

/PRNewswire/ -- Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) (Kazia or the Company), an oncology-focused drug development company, announces its intention...

KZIA : 0.4510 (-19.56%)
KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update regarding...

KZIA : 0.4510 (-19.56%)
KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that data from an...

KZIA : 0.4510 (-19.56%)
KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that its lead...

KZIA : 0.4510 (-19.56%)
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting...

KZIA : 0.4510 (-19.56%)
DAWN : 12.26 (+5.87%)
NVS : 98.13 (+0.23%)
KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, has been invited to the White House to...

KZIA : 0.4510 (-19.56%)
KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to have received notification...

KZIA : 0.4510 (-19.56%)
KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of...

KZIA : 0.4510 (-19.56%)
Beat the Market the Zacks Way: Kazia Therapeutics, Uber, Medtronic in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

ITW : 245.24 (+1.25%)
MDT : 79.99 (+0.91%)
TSCO : 210.07 (+3.48%)
CHD : 95.37 (-1.30%)
ULTA : 472.03 (+10.81%)
OXM : 93.66 (+3.57%)
NOBL : 92.15 (+1.15%)
SWGAY : 13.2200 (+1.23%)
KZIA : 0.4510 (-19.56%)
UBER : 57.35 (+1.72%)
BMWYY : 35.0300 (+0.52%)
Novogen Limited (KZIA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Novogen Limited (KZIA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate...

KZIA : 0.4510 (-19.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being...

See More

Key Turning Points

3rd Resistance Point 0.5340
2nd Resistance Point 0.5170
1st Resistance Point 0.4840
Last Price 0.4510
1st Support Level 0.4340
2nd Support Level 0.4170
3rd Support Level 0.3840

See More

52-Week High 1.6800
Fibonacci 61.8% 1.1611
Fibonacci 50% 1.0007
Fibonacci 38.2% 0.8404
Last Price 0.4510
52-Week Low 0.3215

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar